Label: LEGEND- hyaluronate sodium injection, solution

  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Animal Drug Application

Drug Label Information

Updated November 18, 2021

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    For Intravenous Use In Horses Only

  • SPL UNCLASSIFIED SECTION

    CAUTION:

    Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION

    DESCRIPTION:

    LEGEND Injectable Solution is a clear, colorless solution of low viscosity. LEGEND Injectable Solution is pyrogen free, sterile and does not contain a preservative. It is administered by intravenous injection.

    Hyaluronic acid, the conjugate acid of hyaluronate sodium, is extracted from the capsule of Streptococcus spp. and purified, resulting in a form which is essentially free of protein and nucleic acids.

    LEGEND Injectable Solution is supplied in 4 mL (40 mg) vials. Each mL contains 10 mg hyaluronate sodium, 8.5 mg sodium chloride, 0.223 mg sodium phosphate dibasic, and 0.04 mg sodium phosphate monobasic. The pH is adjusted to between 6.5 and 8.0 with sodium hydroxide or hydrochloric acid.

  • SPL UNCLASSIFIED SECTION

    CHEMISTRY:

    Hyaluronic acid, a glycosaminoglycan, can exist in the following forms depending upon the chemical environment in which it is found: as the acid, hyaluronic acid; as the sodium salt, sodium hyaluronate (hyaluronate sodium); or as the hyaluronate anion. These terms may be used interchangeably but in all cases, reference is made to the glycosaminoglycan composed of repeating subunits of D-glucuronic acid and N-acetyl-D-glucosamine linked together by glycosidic bonds. Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulfate or any other glycosaminoglycan.

  • CLINICAL PHARMACOLOGY

    CLINICAL PHARMACOLOGY:

    Hyaluronic acid is a naturally occurring substance present in connective tissue, skin, vitreous humour and the umbilical cord in all mammals. High concentrations of hyaluronic acid are also found in the synovial fluid. It also constitutes the major component of the capsule of certain microorganisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals.

    The actual mechanism of action for hyaluronate sodium in the healing of degenerative joint disease is not completely understood. One major function appears to be the regulation of normal cellular constituents. This effect decreases the impact of exudation, enzyme release and subsequent degradation of joint integrity. Additionally, hyaluronate sodium exerts an anti-inflammatory action by inhibiting the movement of granulocytes and macrophages.1

    Hyaluronate molecules are long chains which form a filter network interspersed with normal cellular fluids. It is widely accepted that injection directly into the joint pouch enhances the healing of inflamed synovium by restoring lubrication of the joint fluid. This further supplements the visco-elastic properties of normal joint fluid.

  • VETERINARY INDICATIONS

    INDICATIONS:

    LEGEND Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION:

    4 mL (40 mg) injected intravenously. Treatment may be repeated at weekly intervals for a total of three treatments.

    Use aseptic technique and inject slowly into the jugular vein.

    Horses should be given stall rest after treatment before gradually resuming normal activity.

    Discard any unused portion of the drug and empty vial after opening.

  • CONTRAINDICATIONS

    CONTRAINDICATIONS:

    There are no known contraindications for the use of LEGEND Solution in horses.

  • RESIDUE WARNING

    RESIDUE WARNING:

    Do not use in horses intended for human consumption.

  • WARNINGS

    HUMAN WARNINGS:

    Not for use in humans. Keep this and all other drugs out of reach of children.

  • WARNINGS

    ANIMAL SAFETY WARNING:

    Not for Intra-articular use.

  • PRECAUTIONS

    PRECAUTIONS:

    Radiographic evaluation should be carried out in cases of acute lameness to ensure that the joint is free from serious fracture.

    The safety of LEGEND Injectable Solution has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares.

  • ADVERSE REACTIONS

    ADVERSE REACTIONS:

    No local or systemic side effects were observed in the field studies using LEGEND Injectable Solution.

    Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for LEGEND Injectable Solution: Occasional depression, lethargy, and fever.

    To report suspected adverse events, for technical assistance or to obtain a copy of the MSDS, contact Merial at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation.

  • SPL UNCLASSIFIED SECTION

    EFFECTIVENESS:

    Forty-six horses with lameness in either the carpal or fetlock joints were treated intravenously or intra-articularly with LEGEND Injectable Solution in a well-controlled field study conducted at four locations. One, two or three injections were given based on clinical improvement. Overall clinical improvement was judged as excellent or good in 90% of the cases treated intravenously and 96% of those treated intra-articularly with LEGEND Injectable Solution.

  • SPL UNCLASSIFIED SECTION

    ANIMAL SAFETY:

    LEGEND Injectable Solution was administered to normal horses at one, three and five times the recommended intra-articular dosage of 20 mg and intravenous dosage of 40 mg. Treatments were given once weekly for nine consecutive weeks (three times the maximum duration). No systemic clinical signs were observed nor were there any adverse effects upon hematology or clinical chemistry parameters. A transient, slight to mild post injection swelling of the joint capsule occurred in some of the animals treated intra-articularly with LEGEND Injectable Solution as it did in the saline treated control horse. No gross or histological lesions were observed in the soft tissues or the surface areas of the treated joint.

  • STORAGE AND HANDLING

    STORAGE:

    Do not store above 40° C (104° F).

  • HOW SUPPLIED

    HOW SUPPLIED:

    LEGEND Injectable Solution is supplied in a carton of six 4 mL (40 mg) bottles.

    NADA 140-883, Approved by FDA

    Manufactured for: Merial, Inc., Duluth, GA 30096-4640, U.S.A.

  • REFERENCES

    REFERENCE:

    1Swanstrom, O.G. 1978. Hyaluronate (hyaluronic acid) and its use, Proc. American Assoc. Equine Pract., 24th annual convention, pp. 345-348.

  • SPL UNCLASSIFIED SECTION

    ®LEGEND is a registered trademark and the horse logo is a trademark of Merial.
    ©2015 Merial, Inc. All rights reserved.
    Made in USA

    1050-8682-01, Rev. 05-2015

    84671800

  • PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton

    Legend®
    (hyaluronate sodium)
    Injectable Solution 10 mg/mL

    MERIAL

    CAUTION: Federal law restricts this drug to use by or on the order of
    a licensed veterinarian.

    For Intravenous Use in Horses Only

    For the treatment of joint dysfunction of the carpus or fetlock in horses
    due to non-infectious synovitis associated with equine osteoarthritis.

    6 x 4 mL vials

    Manufactured for: Merial, Inc., Duluth, GA 30096-4640, U.S.A.
    NADA 140-883, Approved by FDA

    4mL Vial Carton
  • INGREDIENTS AND APPEARANCE
    LEGEND 
    hyaluronate sodium injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:50604-3141
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    hyaluronate sodium (UNII: YSE9PPT4TH) (hyaluronic acid - UNII:S270N0TRQY) hyaluronate sodium10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Sodium Chloride (UNII: 451W47IQ8X) 8.5 mg  in 1 mL
    SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM (UNII: GR686LBA74) 0.223 mg  in 1 mL
    SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW) 0.04 mg  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:50604-3141-16 in 1 CARTON
    14 mL in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NADANADA14088303/02/2015
    Labeler - Merial, Inc. (799641006)